Commissioner for Health and Food Safety, Stella Kyriakides
Deputy Prime Minister and Minister of Social Affairs and Public Health of Belgium, Frank Vandenbroucke
In a strong European Health Union, everyone must have timely and equal access to medicines. This is the very essence of the work the EU has undertaken over the past few years, in particular through the EU Pharmaceutical Strategy. As part of this objective, addressing shortages and strengthening security of supply of medicines is of great importance for both the Commission and EU Member States.
Today’s launch of the work on a Critical Medicines Alliance will bolster the production of critical medicines in the EU and diversify international supply chains. This is a crucial step in our fight to tackle shortages and reduce the EU’s dependencies on third countries. Building on the successful precedents of the batteries or raw materials alliances, the Critical Medicines Alliance marks the starting point for a new kind of cooperation between the Commission, national governments, industry and civil society. It is a new industrial pillar of the European Health Union to better protect the medicine supply for our patients.
Medicine shortages have increasingly become a concern for patients in the EU. Last winter we saw parents desperately trying to get hold of medicines to treat their children, in some cases travelling hundreds of kilometres. This year, as infections are rising across the EU, people are going to pharmacies and asking for antibiotics that are of limited availability. These are structural problems linked to an increase in shortages in the past years, a situation which is not acceptable.
Beyond the serious consequences for patients when critical medicines are not available, there are also geopolitical concerns which must be addressed. The pandemic and the wars in Europe and the Middle East have shown us very clearly that the structural vulnerabilities in our pharmaceutical supply chains must be addressed as a top political priority. To safeguard our citizens’ health and safety, we must increase Europe’s autonomy when it comes to production and supply of critical medicines.
A Critical Medicines Alliance – changing the game of medicines production and supply chains
The Critical Medicines Alliance will help us set our agenda and change the way we produce and procure medicines to better protect patients. Governments, industry, health professionals and civil society will work together to identify solutions to address the challenge. This could for example mean increasing European production capacity of critical medicines and components by establishing new production lines or constructing new factories. It could also lead to finding new partners abroad to diversify our supply of essential ingredients. As part of Europe’s green and digital transition, we also want the Alliance to promote innovation and support the modernisation of EU production capacity.
As a first step towards setting up the Alliance, interested experts from Member States, industry, health professionals, and civil society are invited to take part in the selection procedure for the Alliance that runs until 16 February, in view of participating in its meetings in Spring 2024.
In the meantime, the Commission will start analysing the supply chain vulnerabilities for a number of critical medicines for which the Alliance will develop recommendations on actions to take to improve their supply. The Alliance will also support and channel the investments needed at national and EU level to deliver on its ambitious objectives.
Fighting shortages of medicines in our Member States of course does not mean closing the door to our international partners. With the support of the Alliance, the EU will simultaneously work towards stronger international partnerships to diversify supply chains and enhance security of medicines supply globally.
The work of the Alliance will be pivotal in maintaining our global leadership and enhancing the competitiveness of the pharmaceutical sector. Above all, these are crucial steps in safeguarding the health and well-being of Europeans. With the launch of the Critical Medicines Alliance, we are opening a new, industrial chapter for a European Health Union determined to turn vision into reality.




